Mycenax Biotech Overview

  • Founded
  • 2001

Founded
  • Status
  • Public

  • Employees
  • 325

Employees
  • Stock Symbol
  • 4726

Stock Symbol
  • Share Price
  • $1.26

  • (As of Tuesday Closing)

Mycenax Biotech General Information

Description

Mycenax Biotech Inc is a Taiwan based biopharmaceutical company. It is engaged in the development and manufacture of biopharmaceutical products, specializing in mammalian and microbial cell-derived biologics. The company's pipeline products include TuNEX(opinercept - lyophilizate), TuNEX(opinercept - solution), LusiNEX (tocilizumab), and Omalizumab.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
ROCO
Primary Office
  • Research Zhunan Road
  • 4th Floor, 50-7 Keyan Road
  • Zhunan, Miaoli County 350-53
  • Taiwan
+886 03 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mycenax Biotech Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.26 $1.25 $1.12 - $1.84 $195M 155M 4.72M -$0.05

Mycenax Biotech Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 227,350 216,278 142,360 88,865
Revenue 26,624 27,707 22,603 12,648
EBITDA (652) 2,953 5,590 (3,527)
Net Income (8,253) (3,216) 1,051 (7,060)
Total Assets 108,466 113,368 62,831 47,011
Total Debt 29,129 26,330 7,049 1,563
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Mycenax Biotech Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Mycenax Biotech‘s full profile, request access.

Request a free trial

Mycenax Biotech Patents

Mycenax Biotech Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-1253942-A1 Cd40-binding apc-activating molecules Inactive 01-Feb-2000 000000000000
US-7820807-B2 Can bind to and stimulate professional and non-professional human antigen-presenting cells, enhance the stimulatory effect of cd40l on cd40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells Inactive 01-Feb-2000 000000000000
US-20090311268-A1 Can bind to and stimulate professional and non-professional human antigen-presenting cells, enhance the stimulatory effect of cd40l on cd40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells Active 01-Feb-2000 000000000000
US-20070098720-A1 Bind to cell surface receptor, induce intracellular signal transduction, leading to activation of antigen presenting cells (apc) expressing cd40; cytotoxic effects, useful as antitumor agents Active 01-Feb-2000 000000000000
US-20010026932-A1 Agonist anti-cd40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells; may be useful as antitumor agents Active 01-Feb-2000 A61K39/39541 0
To view Mycenax Biotech’s complete patent history, request access »

Mycenax Biotech Executive Team (1)

Name Title Board Seat Contact Info
Karen Wen Founder & President
To view Mycenax Biotech’s complete executive team members history, request access »

Mycenax Biotech Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial